单位：[1]Department of Respiratory Diseases, China-Japan Friendship Hospital, Peking University, Beijing 100029, China[2]State Key Laboratory of Respiratory Disease, Department of Allergy and Clinical Immunology, Guangzhou Institute of Respiratory Disease, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China[3]Department of Respiratory Medicine, Affiliated Hospital of Qingdao Medical College, Qingdao 266071, China[4]Department of Respiratory Medicine, Sichuan Provincial People's Hospital, Chengdu 610072, China四川省人民医院[5]Department of Respiratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China四川大学华西医院[6]Department of Respiratory Medicine, The Second Xiangya Hospital of Central South University, Changsha 410011, China[7]Department of Respiratory and Critical Care, The First Affiliated Hospital of Baotou Medical College, Baotou 014040, China内蒙古科技大学包头医学院[8]Department of Respiratory Medicine, Peking University Third Hospital, Beijing 100191, China[9]Department of Respiratory and Critical Care, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China首都医科大学附属安贞医院[10]Department of Respiratory Medicine, Southwest Hospital, 1st Affiliated Hospital of Third Military Medical University, Chongqing 400038, China
Background: To assess the level of asthma control achieved with budesonide/formoterol in Chinese patients with asthma, based on the Global Initiative for Asthma (GINA) definition and Asthma Control Test (ACT) score. Methods: This multicenter, cross-sectional study (NCT01785901) evaluated asthma control levels in Chinese patients receiving physician -prescribed budesonide/formoterol treatment. Adults with a diagnosis of asthma >6 months and receiving budesonide/formoterol treatment >3 months before screening were consecutively enrolled. Data including medical and medication history were collected using faceto-face questionnaires and physical examinations during a single visit. Results: A total of 1483 asthma out-patients from 27 medical centers were enrolled; 217 (14.6%) were treated with budesonide/formoterol using a fixed-dose strategy-and 1266 (85.4%) with the SMART (Symbicort Maintenance And Reliever Therapy) strategy. According to GINA criteria, asthma was controlled in 58.6% (95% CI: 56.1%-61.1%) of patients and was either controlled or partly controlled in 94.1% (95% CI: 92.8%-95.3%) of patients. According to ACT score, asthma was completely controlled in 22.4% (95% CI: 20.3%-24.6%) of patients and was either completely or well controlled in 83.3% (95% CI: 81.4%-85.2%) of patients. Multivariate logistic regression analysis revealed that a >-5-Year history of asthma and an age of >50 years were factors associated with lower levels of asthma control. Conclusions: This study demonstrated high levels of asthma control (GINA: controlled and partly controlled and ACT: completely and well controlled) in Chinese patients with asthma treated with 'budesonideiformoterol. Greater age and a longer disease history were associated with lower levels of asthma control. (C) 2017 Elsevier Ltd. All rights reserved.
基金：
AstraZenecaAstraZeneca
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2016]版：
大类|3 区医学
小类|3 区心脏和心血管系统3 区呼吸系统
最新[2025]版：
大类|3 区医学
小类|3 区心脏和心血管系统3 区呼吸系统
JCR分区：
出版当年[2015]版：
Q2RESPIRATORY SYSTEMQ2CARDIAC & CARDIOVASCULAR SYSTEMS
最新[2023]版：
Q2CARDIAC & CARDIOVASCULAR SYSTEMSQ2RESPIRATORY SYSTEM
第一作者单位：[1]Department of Respiratory Diseases, China-Japan Friendship Hospital, Peking University, Beijing 100029, China[*1]Department of Respiratory Diseases, China-Japan Friendship Hospital, Peking University, No.2 Yinghua East Street, Chaoyang District, Beijing 100029, China
通讯作者：
通讯机构：[1]Department of Respiratory Diseases, China-Japan Friendship Hospital, Peking University, Beijing 100029, China[*1]Department of Respiratory Diseases, China-Japan Friendship Hospital, Peking University, No.2 Yinghua East Street, Chaoyang District, Beijing 100029, China
推荐引用方式(GB/T 7714)：
Lin Jiangtao,Li Jing,Yu Wencheng,et al.A multicenter, cross-sectional, observational study of budesonide/formoterol maintenance and reliever therapy in real-world settings[J].RESPIRATORY MEDICINE.2017,127:45-50.doi:10.1016/j.rmed.2017.04.004.
APA：
Lin, Jiangtao,Li, Jing,Yu, Wencheng,Liu, Yuejian,Liu, Chuntao...&Zhou, Xiangdong.(2017).A multicenter, cross-sectional, observational study of budesonide/formoterol maintenance and reliever therapy in real-world settings.RESPIRATORY MEDICINE,127,
MLA：
Lin, Jiangtao,et al."A multicenter, cross-sectional, observational study of budesonide/formoterol maintenance and reliever therapy in real-world settings".RESPIRATORY MEDICINE 127.(2017):45-50
